BACKGROUND: The non-nucleoside reverse transcriptase inhibitors are novel antiretroviral agents with selective activity in vitro against human immunodeficiency virus type 1 (HIV-1). They act through direct inhibition of reverse transcriptase and are not incorporated into DNA. METHODS: We evaluated a pyridinone non-nucleoside reverse transcriptase inhibitor, L-697,661, in separate six-week double-blind trials in patients with HIV-1 infection whose CD4 counts ranged from 200 to 500 cells per cubic millimeter (68 patients) or less than 200 cells per cubic millimeter (67 patients). Eligible patients were randomly assigned to receive L-697,661 orally in one of three doses (25 mg twice a day, 100 mg three times a day, or 500 mg twice a day) or zidovudine (100 mg five times a day). Clinical and laboratory assessments were performed weekly. Viral isolates were obtained from a subgroup of patients before and after treatment and were evaluated for in vitro sensitivity to L-697,661. RESULTS: Both L-697,661 and zidovudine were well tolerated. Transient increases in CD4 counts were noted in the patients with fewer than 200 CD4 cells per cubic millimeter who received the two higher doses of L-697,661, but not in those who received the lowest dose or zidovudine. Patients who received L-697,661 had rapid, dose-related decreases in plasma p24 antigen levels. However, this response virtually disappeared after six weeks in some patients receiving L-697,661, coincidently with the emergence of resistant viruses. This change in susceptibility was more frequent among patients receiving the higher doses of L-697,661 and was associated with amino acid substitutions at positions 103 and 181 in the HIV-1 reverse transcriptase gene. CONCLUSIONS:L-697,661 is safe and well tolerated and has significant dose-related activity against HIV-1. However, resistant strains of the virus emerge rapidly and may limit the effectiveness of non-nucleoside reverse transcriptase inhibitors as monotherapy for HIV-1 infection.
RCT Entities:
BACKGROUND: The non-nucleoside reverse transcriptase inhibitors are novel antiretroviral agents with selective activity in vitro against human immunodeficiency virus type 1 (HIV-1). They act through direct inhibition of reverse transcriptase and are not incorporated into DNA. METHODS: We evaluated a pyridinone non-nucleoside reverse transcriptase inhibitor, L-697,661, in separate six-week double-blind trials in patients with HIV-1 infection whose CD4 counts ranged from 200 to 500 cells per cubic millimeter (68 patients) or less than 200 cells per cubic millimeter (67 patients). Eligible patients were randomly assigned to receive L-697,661 orally in one of three doses (25 mg twice a day, 100 mg three times a day, or 500 mg twice a day) or zidovudine (100 mg five times a day). Clinical and laboratory assessments were performed weekly. Viral isolates were obtained from a subgroup of patients before and after treatment and were evaluated for in vitro sensitivity to L-697,661. RESULTS: Both L-697,661 and zidovudine were well tolerated. Transient increases in CD4 counts were noted in the patients with fewer than 200 CD4 cells per cubic millimeter who received the two higher doses of L-697,661, but not in those who received the lowest dose or zidovudine. Patients who received L-697,661 had rapid, dose-related decreases in plasma p24 antigen levels. However, this response virtually disappeared after six weeks in some patients receiving L-697,661, coincidently with the emergence of resistant viruses. This change in susceptibility was more frequent among patients receiving the higher doses of L-697,661 and was associated with amino acid substitutions at positions 103 and 181 in the HIV-1 reverse transcriptase gene. CONCLUSIONS:L-697,661 is safe and well tolerated and has significant dose-related activity against HIV-1. However, resistant strains of the virus emerge rapidly and may limit the effectiveness of non-nucleoside reverse transcriptase inhibitors as monotherapy for HIV-1 infection.
Authors: R W Buckheit; K Watson; V Fliakas-Boltz; J Russell; T L Loftus; M C Osterling; J A Turpin; L A Pallansch; E L White; J W Lee; S H Lee; J W Oh; H S Kwon; S G Chung; E H Cho Journal: Antimicrob Agents Chemother Date: 2001-02 Impact factor: 5.191
Authors: R A Olmsted; D E Slade; L A Kopta; S M Poppe; T J Poel; S W Newport; K B Rank; C Biles; R A Morge; T J Dueweke; Y Yagi; D L Romero; R C Thomas; S K Sharma; W G Tarpley Journal: J Virol Date: 1996-06 Impact factor: 5.103
Authors: J P Vacca; B D Dorsey; W A Schleif; R B Levin; S L McDaniel; P L Darke; J Zugay; J C Quintero; O M Blahy; E Roth Journal: Proc Natl Acad Sci U S A Date: 1994-04-26 Impact factor: 11.205
Authors: G D Morse; M A Fischl; M J Shelton; M T Borin; M R Driver; M DeRemer; K Lee; C P Wajszczuk Journal: Antimicrob Agents Chemother Date: 1996-03 Impact factor: 5.191
Authors: Daria J Hazuda; Neville J Anthony; Robert P Gomez; Samson M Jolly; John S Wai; Linghang Zhuang; Thorsten E Fisher; Mark Embrey; James P Guare; Melissa S Egbertson; Joseph P Vacca; Joel R Huff; Peter J Felock; Marc V Witmer; Kara A Stillmock; Robert Danovich; Jay Grobler; Michael D Miller; Amy S Espeseth; Lixia Jin; I-Wu Chen; Jiunn H Lin; Kelem Kassahun; Joan D Ellis; Bradley K Wong; Wei Xu; Paul G Pearson; William A Schleif; Riccardo Cortese; Emilio Emini; Vincenzo Summa; M Katharine Holloway; Steven D Young Journal: Proc Natl Acad Sci U S A Date: 2004-07-26 Impact factor: 11.205